Yeast genetic screen reveals novel therapeutic strategy for ALS

References

• Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know?. Nat Rev Neurol 2011; 7:603 - 15; http://dx.doi.org/10.1038/nrneurol.2011.150; PMID: 21989245
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59 - 62; http://dx.doi.org/10.1038/362059a0; PMID: 8446170
   PubMed Web of Science ®Google Scholar
• Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9:4 - 15; http://dx.doi.org/10.1080/17482960701856300; PMID: 18273714
   PubMed Web of Science ®Google Scholar
• Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7:639 - 49; http://dx.doi.org/10.1038/nrneurol.2011.153; PMID: 21989247
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130 - 3; http://dx.doi.org/10.1126/science.1134108; PMID: 17023659
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell 2009; 136:1001 - 4; http://dx.doi.org/10.1016/j.cell.2009.03.006; PMID: 19303844
   PubMed Web of Science ®Google Scholar
• Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010; 6:211 - 20; http://dx.doi.org/10.1038/nrneurol.2010.18; PMID: 20234357
   PubMed Web of Science ®Google Scholar
• Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180 - 9; http://dx.doi.org/10.1001/archneurol.2008.558; PMID: 19204154
   PubMed Web of Science ®Google Scholar
• Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466:1069 - 75; http://dx.doi.org/10.1038/nature09320; PMID: 20740007
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245 - 56; http://dx.doi.org/10.1016/j.neuron.2011.09.011; PMID: 21944778
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al, ITALSGEN Consortium. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257 - 68; http://dx.doi.org/10.1016/j.neuron.2011.09.010; PMID: 21944779
   PubMed Web of Science ®Google Scholar
• Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol 2011; 21:904 - 19; http://dx.doi.org/10.1016/j.conb.2011.05.029; PMID: 21813273
   PubMed Web of Science ®Google Scholar
• Gitler AD, Lehmann R. Modeling human disease. Science 2012; 337:269; http://dx.doi.org/10.1126/science.1227179; PMID: 22822114
   PubMed Web of Science ®Google Scholar
• Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2008; 105:6439 - 44; http://dx.doi.org/10.1073/pnas.0802082105; PMID: 18434538
   PubMed Web of Science ®Google Scholar
• Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 2011; 9:e1000614; http://dx.doi.org/10.1371/journal.pbio.1000614; PMID: 21541367
   PubMed Web of Science ®Google Scholar
• Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003; 302:1772 - 5; http://dx.doi.org/10.1126/science.1090439; PMID: 14657500
   PubMed Web of Science ®Google Scholar
• Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 2003; 302:1769 - 72; http://dx.doi.org/10.1126/science.1090389; PMID: 14657499
   PubMed Web of Science ®Google Scholar
• Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 2006; 313:324 - 8; http://dx.doi.org/10.1126/science.1129462; PMID: 16794039
   PubMed Web of Science ®Google Scholar
• Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 2009; 41:308 - 15; http://dx.doi.org/10.1038/ng.300; PMID: 19182805
   PubMed Web of Science ®Google Scholar
• Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A 2000; 97:1589 - 94; http://dx.doi.org/10.1073/pnas.97.4.1589; PMID: 10677504
   PubMed Web of Science ®Google Scholar
• Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005; 37:526 - 31; http://dx.doi.org/10.1038/ng1542; PMID: 15806102
   PubMed Web of Science ®Google Scholar
• Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, Baru V, et al. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast. Science 2011; 334:1241 - 5; http://dx.doi.org/10.1126/science.1213210; PMID: 22033521
   PubMed Web of Science ®Google Scholar
• Su LJ, Auluck PK, Outeiro TF, Yeger-Lotem E, Kritzer JA, Tardiff DF, et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models. Dis Model Mech 2010; 3:194 - 208; http://dx.doi.org/10.1242/dmm.004267; PMID: 20038714
   PubMed Web of Science ®Google Scholar
• Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, et al. A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 2011; 9:e1001052; http://dx.doi.org/10.1371/journal.pbio.1001052; PMID: 21541368
   PubMed Web of Science ®Google Scholar
• Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009; 284:20329 - 39; http://dx.doi.org/10.1074/jbc.M109.010264; PMID: 19465477
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011; 14:459 - 68; http://dx.doi.org/10.1038/nn.2779; PMID: 21358643
   PubMed Web of Science ®Google Scholar
• Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 2010; 30:639 - 49; http://dx.doi.org/10.1523/JNEUROSCI.4988-09.2010; PMID: 20071528
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319:1668 - 72; http://dx.doi.org/10.1126/science.1154584; PMID: 18309045
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2009; 106:7607 - 12; http://dx.doi.org/10.1073/pnas.0900688106; PMID: 19383787
   PubMed Web of Science ®Google Scholar
• Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 2010; 30:7729 - 39; http://dx.doi.org/10.1523/JNEUROSCI.5894-09.2010; PMID: 20519548
   PubMed Web of Science ®Google Scholar
• Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, et al. Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 2010; 19:671 - 83; http://dx.doi.org/10.1093/hmg/ddp534; PMID: 19959528
   PubMed Web of Science ®Google Scholar
• Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci 2010; 30:16208 - 19; http://dx.doi.org/10.1523/JNEUROSCI.2911-10.2010; PMID: 21123567
   PubMed Web of Science ®Google Scholar
• Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, et al. A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A 2010; 107:3169 - 74; http://dx.doi.org/10.1073/pnas.0913602107; PMID: 20133767
   PubMed Web of Science ®Google Scholar
• Lee T, Li YR, Chesi A, Hart MP, Ramos D, Jethava N, et al. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis. Neurology 2011; 76:2062 - 5; http://dx.doi.org/10.1212/WNL.0b013e31821f4447; PMID: 21562248
   PubMed Web of Science ®Google Scholar
• Van Damme P, Veldink JH, van Blitterswijk M, Corveleyn A, van Vught PW, Thijs V, et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011; 76:2066 - 72; http://dx.doi.org/10.1212/WNL.0b013e31821f445b; PMID: 21562247
   PubMed Web of Science ®Google Scholar
• Ross OA, Rutherford NJ, Baker M, Soto-Ortolaza AI, Carrasquillo MM, DeJesus-Hernandez M, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 2011; 20:3207 - 12; http://dx.doi.org/10.1093/hmg/ddr227; PMID: 21610160
   PubMed Web of Science ®Google Scholar
• Fischbeck KH, Pulst SM. Amyotrophic lateral sclerosis and spinocerebellar ataxia 2. Neurology 2011; 76:2050 - 1; http://dx.doi.org/10.1212/WNL.0b013e31821f4498; PMID: 21562249
   PubMed Web of Science ®Google Scholar
• Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, Diaz Z, et al. Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 2012; 44:1302 - 9; http://dx.doi.org/10.1038/ng.2434; PMID: 23104007
   PubMed Web of Science ®Google Scholar
• Chapman KB, Boeke JD. Isolation and characterization of the gene encoding yeast debranching enzyme. Cell 1991; 65:483 - 92; http://dx.doi.org/10.1016/0092-8674(91)90466-C; PMID: 1850323
   PubMed Web of Science ®Google Scholar
• Khalid MF, Damha MJ, Shuman S, Schwer B. Structure-function analysis of yeast RNA debranching enzyme (Dbr1), a manganese-dependent phosphodiesterase. Nucleic Acids Res 2005; 33:6349 - 60; http://dx.doi.org/10.1093/nar/gki934; PMID: 16275784
   PubMed Web of Science ®Google Scholar
• Haim-Vilmovsky L, Gerst JE. m-TAG: a PCR-based genomic integration method to visualize the localization of specific endogenous mRNAs in vivo in yeast. Nat Protoc 2009; 4:1274 - 84; http://dx.doi.org/10.1038/nprot.2009.115; PMID: 19680241
   PubMed Web of Science ®Google Scholar
• Hilleren PJ, Parker R. Cytoplasmic degradation of splice-defective pre-mRNAs and intermediates. Mol Cell 2003; 12:1453 - 65; http://dx.doi.org/10.1016/S1097-2765(03)00488-X; PMID: 14690599
   PubMed Web of Science ®Google Scholar
• Weil TT, Parton RM, Davis I. Making the message clear: visualizing mRNA localization. Trends Cell Biol 2010; 20:380 - 90; http://dx.doi.org/10.1016/j.tcb.2010.03.006; PMID: 20444605
   PubMed Web of Science ®Google Scholar
• Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A 2011; 108:20881 - 90; http://dx.doi.org/10.1073/pnas.1109434108; PMID: 22065782
   PubMed Web of Science ®Google Scholar
• Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 2012; 21:2899 - 911; http://dx.doi.org/10.1093/hmg/dds116; PMID: 22454397
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495:467 - 73; http://dx.doi.org/10.1038/nature11922; PMID: 23455423
   PubMed Web of Science ®Google Scholar
• King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012; 1462:61 - 80; http://dx.doi.org/10.1016/j.brainres.2012.01.016; PMID: 22445064
   PubMed Web of Science ®Google Scholar